Mitsubishi UFJ Asset Management Co. Ltd. Has $76.91 Million Stake in Zoetis Inc. $ZTS

Mitsubishi UFJ Asset Management Co. Ltd. trimmed its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 74.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,070,271 shares of the company's stock after selling 3,174,080 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.26% of Zoetis worth $76,910,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. J. Stern & Co. LLP lifted its stake in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company's stock valued at $3,028,423,000 after acquiring an additional 23,877,416 shares in the last quarter. Norges Bank bought a new position in shares of Zoetis during the 4th quarter worth approximately $734,425,000. Vanguard Group Inc. grew its stake in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company's stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares in the last quarter. Ruane Cunniff & Goldfarb L.P. acquired a new stake in shares of Zoetis in the first quarter valued at approximately $286,660,000. Finally, Van ECK Associates Corp raised its holdings in shares of Zoetis by 269.0% in the fourth quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company's stock valued at $300,340,000 after purchasing an additional 1,740,113 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ZTS has been the subject of several recent research reports. Citigroup reduced their target price on shares of Zoetis from $112.00 to $96.00 and set a "buy" rating for the company in a report on Tuesday, August 11th. Barclays lowered their price target on shares of Zoetis from $136.00 to $85.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 1st. Piper Sandler cut their price target on shares of Zoetis from $90.00 to $80.00 and set a "neutral" rating on the stock in a research report on Monday, August 10th. HSBC reduced their price objective on shares of Zoetis from $140.00 to $95.00 and set a "buy" rating for the company in a research note on Monday, July 6th. Finally, UBS Group lowered their target price on Zoetis from $85.00 to $80.00 and set a "neutral" rating on the stock in a research report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $109.62.

Zoetis Trading Up 1.5%

NYSE ZTS opened at $74.04 on Wednesday. The company has a market cap of $30.60 billion, a PE ratio of 12.20, a PEG ratio of 1.28 and a beta of 0.73. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 12 month low of $71.00 and a 12 month high of $160.48. The stock has a 50 day moving average of $76.01 and a 200-day moving average of $98.13.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts' expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm's revenue was down .2% on a year-over-year basis. During the same period last year, the business earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source